Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression

Ghasimi, Soma; Haapasalo, Hannu; Eray, Mine; Korhonen, Katariina; Brännström, Thomas; Hedman, Håkan; Andersson, Ulrika

doi:10.1007/s11060-012-0856-x

Cited by 14 publications

(11 citation statements)

References 37 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ghasimi and co-workers analyzed LRIG expression in 409 meningioma cases via immunohistochemistry [ 62 ]. Expression of both LRIG1 and LRIG2 correlated with estrogen receptor status, which is consistent with the finding that LRIG1 is regulated by estrogen signaling in breast cancer [ 1 ].…”

Section: Resultsmentioning

confidence: 99%

LRIG and cancer prognosis

et al. 2014

Self Cite

View full text Add to dashboard Cite

BackgroundOptimal treatment decisions for cancer patients require reliable prognostic and predictive information. However, this information is inadequate in many cases. Several recent studies suggest that the leucine-rich repeats and immunoglobulin-like domains (LRIG) genes, transcripts, and proteins have prognostic implications in various cancer types.Material and methodsRelevant literature was identified on PubMed using the key words lrig1, lrig2, and lrig3. LRIG mRNA expression in cancer versus normal tissues was investigated using the Oncomine database.ResultsThe three human LRIG genes, LRIG1, LRIG2, and LRIG3, encode single-pass transmembrane proteins. LRIG1 is a negative regulator of growth factor signaling that has been shown to function as a tumor suppressor in vitro and in vivo in mice. The functions of LRIG2 and LRIG3 are less well defined. LRIG gene and protein expression are commonly dysregulated in human cancer. In early stage breast cancer, LRIG1 copy number was recently shown to predict early and late relapse in addition to overall survival; in nasopharyngeal carcinoma, loss of LRIG1 is also associated with poor survival. LRIG gene and protein expression have prognostic value in breast cancer, uterine cervical cancer, head-and-neck cancer, glioma, non-small cell lung cancer, prostate cancer, and cutaneous squamous cell carcinoma. In general, expression of LRIG1 and LRIG3 is associated with good survival, whereas expression of LRIG2 is associated with poor survival. Additionally, LRIG1 regulates cellular sensitivity to anti-cancer drugs, which indicates a possible role as a predictive marker.ConclusionsLRIG gene statuses and mRNA and protein expression are clinically relevant prognostic indicators in several types of human cancer. We propose that LRIG analyses could become important when making informed and individualized clinical decisions regarding the management of cancer patients.

show abstract

Section: Resultsmentioning

confidence: 99%

LRIG and cancer prognosis

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly, LRIG2 expression was found to correlate with increased FHIT and p16 4INKa , as well as IL-10 expression, while a negative correlation was observed with Rb and Ki-67 expression (21). In meningiomas, the LRIG2 expression in the cytoplasm of has been found to correlate with estrogen receptor (ER) status and histological subtype, with the benign subtypes most frequently expressing LRIG2 (22). Recently, emerging evidence has indicated that the hormones, estrogen and progesterone, are key in the progression of NSCLC (23).…”

Section: Discussionmentioning

confidence: 99%

LRIG2 expression and prognosis in non-small cell lung cancer

Wang

Song

2014

Oncology Letters

View full text Add to dashboard Cite

The human leucine-rich repeats and immunoglobulin-like domains 2 (LRIG2) protein has been shown to be of prognostic value in several types of human cancer, however, the expression profiles of LRIG2 have not been described in non-small cell lung cancer (NSCLC). The present study evaluated the mRNA expression of LRIG2 in tumor specimens obtained from 39 NSCLC patients by SYBR Green quantitative polymerase chain reaction and the protein expression of LRIG2 in formalin-fixed paraffin sections obtained from 116 NSCLC patients by immunohistochemistry. The correlations between LRIG2 expression and clinicopathological data were analyzed. The patient survival data were collected retrospectively and the possible prognostic value of LRIG2 protein expression was investigated. The results showed that the mRNA expression of LRIG2 was decreased in NSCLC cancer tissues, which was associated with histological subtypes and tumor differentiation status. The protein expression of LRIG2 was only observed in the cytoplasm of the tumor tissue, which conformed to the mRNA expression results. Furthermore, the patients with high LRIG2 cytoplasmic expression showed poor survival times, and the five-year survival rate for patients with high LRIG2 expression was 27.8%, compared with 38.8% for patients with low expression (P=0.034), indicating that LRIG2 expression levels may have a potential role in the pathogenesis of NSCLC, and also a significant prognostic value. Further studies are required to fully elucidate the exact function of LRIG2 in NSCLC.

show abstract

“…LRIG2 modulates cell turnover and adhesion in neural support cells via altered growth-factor signaling, 21 and altered LRIG2 localization occurs in various types of neural tumors. [22][23][24] Detection of LUT abnormalities antenatally and abnormal grimacing in infancy implies that pathogenic mechanisms underlying UFS initiate during development. Indeed, in embryonic mice, VII nerve ganglia express Lrig2.…”

mentioning

confidence: 99%

LRIG2 Mutations Cause Urofacial Syndrome

Stuart

Roberts

Burgu

et al. 2013

The American Journal of Human Genetics

View full text Add to dashboard Cite

Urofacial syndrome (UFS) (or Ochoa syndrome) is an autosomal-recessive disease characterized by congenital urinary bladder dysfunction, associated with a significant risk of kidney failure, and an abnormal facial expression upon smiling, laughing, and crying. We report that a subset of UFS-affected individuals have biallelic mutations in LRIG2, encoding leucine-rich repeats and immunoglobulin-like domains 2, a protein implicated in neural cell signaling and tumorigenesis. Importantly, we have demonstrated that rare variants in LRIG2 might be relevant to nonsyndromic bladder disease. We have previously shown that UFS is also caused by mutations in HPSE2, encoding heparanase-2. LRIG2 and heparanase-2 were immunodetected in nerve fascicles growing between muscle bundles within the human fetal bladder, directly implicating both molecules in neural development in the lower urinary tract.

show abstract

Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression

Cited by 14 publications

References 37 publications

LRIG and cancer prognosis

LRIG and cancer prognosis

LRIG2 expression and prognosis in non-small cell lung cancer

LRIG2 Mutations Cause Urofacial Syndrome

Contact Info

Product

Resources

About